glp-1 psoriatic arthritis Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions GLP-1 Medications for Arthritis &

The study, led by Astrup A and Madsbad S, involved obese subjects who received different doses of Tesofensine or a placebo for 24 weeks

Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids

Strategies on how to manage these and other side effects are described in more detail here: Figure 3 of this article and Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists

The combination therapy also resulted in a slight but statistically non-significant increase in visceral adipose tissue TBR values, whereas CPAP did not affect VAT TBR